Amazon ( AMZN) led a postbell tech melee Tuesday, as profit-takers emerged in droves despite better-than-expected earnings at the online retailer. Seattle-based Amazon's third-quarter profit nearly quadrupled year-over-year to 19 cents a share, or $80 million. The company posted revenue of $3.26 billion, a 41.4% gain. Wall Street was seeking 18 cents a share on $3.14 billion in sales. Still, shares slid $10.60, or 10.5%, to $90.22. Similarly, chipmaker RF Micro Devices ( RFMD) slid 6.1% to $6.78, even though it topped earnings and revenue targets for the fiscal second quarter. The Greensboro, N.C., company also warned that its manufacturing operations are having trouble keeping up with strong demand, which is eating into profit margins in the current quarter. Riverbed Technology ( RVBD) dipped 22.1%, one of the biggest price drops after-hours , even though earnings met expectations and revenue was above par. Broadcom ( BRCM) was off 10.9% after non-GAAP third-quarter earnings slid 15.6% to an in-line 27 cents a share. Fellow chipmaker Altera ( ALTR) projected next-quarter sales to be flat to down 4% sequentially, and information-technology firm Savvis ( SVVS) pegged fourth-quarter revenue at $197 million to $200 million. That's at least $7.2 million under consensus. Both firms posted better-than-expected third-quarter profits, but Altera shares were still down 12.1% to $20.50 and Savvis was sinking 12.7% to $36.05. Out of the tech sector, Illumina ( ILMN) said non-GAAP third-quarter earnings fell 12.8% to 34 cents a share. Although that's 15 cents higher than the Street's per-share estimates, shares of the San Diego biotech company shed 5.8% to $58.79. On the other hand, QLogic ( QLGC) climbed 4.3% to $14.06, after beating analysts' fiscal second-quarter expectations with non-GAAP income of $32.5 million, or 22 cents a share, on sales of $140.3 million. The Street was expecting 19 cents a share on revenue of $139.4 million. And drugmaker Cephalon ( CEPH), of Frazer, Pa., said its late-phase study of cancer drug Treanda met the primary endpoints for overall response rate and median duration of response. The drug is proposed for patients with indolent (or slow-growing) non-Hodgkin's lymphoma whose cancer is no longer responsive to treatment with rituximab. Cephalon also said that Treanda exhibited a "manageable tolerability profile." Shares were rising $1.92, or 2.7%, to $73.